Pharmaceuticals company Supriya Lifescience announced Q1FY26 results The company witnessed a 9.7% YoY decline in Revenue to Rs 145.07 crore compared to Rs 160.63 crore in Q1FY25. EBITDA for Q1FY26 stood at Rs. 51.70 crore, with an EBITDA margin of 35.6%, as against Rs 62.54 crore in Q1FY25 with a margin of 38.9%. The Profit After Tax (PAT) for Q1FY26 was Rs 34.79 crore, compared to RS 44.64 crore in Q1FY25. The PAT Margin stood at 24.0% in Q1FY26 versus 27.8% in Q1FY25. Anaesthetic segment led the revenue in Q1, contributing 53% to the revenue vs 45% in Q1FY25. European markets now contribute 41% of our business revenue in Q1FY26, up from 34% in Q1FY25. Satish Wagh, Chairman & Managing Director, Supriya Lifescience, said: “Our Q1 results reflect a temporary impact from the delay in the production facility campaign due to essential repair and maintenance at our Lote facility. These upgrades were critical to improving the efficiency of our older blocks and enabling full utilisation of Module E for upcoming product launches. Despite the revenue dip, EBITDA margins remained strong at 36%, backed by improved backwards integration and increased contribution from regulated markets. With the Ambernath site progressing towards commercial production in Q4, a strong pipeline of 3 to 4 product launches in FY26, and healthy demand across key therapeutic areas, we expect the second half to recover the delays from H1. We remain on track to deliver ~20% growth and reach Rs 1,000 crore revenue by FY27." Result PDF
Pharmaceuticals company Supriya Lifescience announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: In the fourth quarter of FY25, Supriya Lifescience Ltd. witnessed remarkable growth in its revenue, reporting a 16.4 % year-over-year increase, reaching Rs 184.11 crore compared to Rs 158.18 crore in Q4FY24. EBITDA for Q4FY25 stood at Rs 67.58 crore, with an EBITDA Margin of 36.7 %, as opposed to an EBITDA of Rs 55.5 crore in Q4FY24 with an EBITDA margin of 35.1%. This marks an improvement of 162 bps YoY. Profit after Tax for Q4FY25 stood at Rs 50.38 crore, with a growth of 38.4% compared to Rs 36.40 crore in Q4FY24. The PAT Margin stood at 27.4% in Q4FY25, compared to 23.0% in Q4FY24 FY25 Financial Highlights: In FY25, Supriya Lifescience Ltd. witnessed remarkable growth in its revenue, reporting a 22% year-over-year increase, reaching Rs 696.48 crore compared to Rs 570.37 crore in FY24. EBITDA for FY25 stood at Rs 260.80 crore, with an EBITDA Margin of 37.4 %, as opposed to an EBITDA of Rs 172.98 crore in FY24 with an EBITDA margin of 30.3%. This marks an improvement of 712 bps YoY. Profit after Tax for FY25 stood at Rs 187.96 crore, with a growth of 57.8% compared to Rs 119.11 crore in FY24. The PAT Margin stood at 27.0% in FY25, compared to 20.9% in FY24. Satish Wagh, Chairman and Whole Time Director, Supriya Lifescience commenting on the results, said, “FY25 has been a landmark year for Supriya Lifescience, reflecting the strength of our diversified product portfolio, resilient global operations, and consistent focus on operational excellence. We achieved our highest-ever annual revenue of Rs 697 crore, up 22% year-on-year, and delivered an EBITDA of Rs 261 crore with a robust margin of 37.4%. In Q4FY25, revenue grew by 16.4% to Rs 184.11 crore, while PAT rose by 38.4% to Rs 50.38 crore, supported by improved margins. Our strategic focus on high-value therapeutic segments, deeper penetration in regulated markets, and strengthened backward integration continue to drive our performance. We remain committed to building on this momentum to deliver sustainable growth, foster innovation, and create long-term value for all stakeholders.” Result PDF
Pharmaceuticals company Supriya Lifescience announced Q3FY25 results In the third quarter of FY25, Supriya Lifescience witnessed remarkable growth in its revenue, reporting a 33% year-over-year increase, reaching Rs 185.65 crore compared to Rs 140.07 crore in Q3FY24. Gross Profit for Q3FY25 stood at Rs 123.87 crore, with a growth of 45% compared to Rs 85.45 crore in Q3FY24. EBITDA for Q3FY25 stood at Rs 65.95 crore, with an EBITDA Margin of 35.50%, as opposed to an EBITDA of Rs 41.49 crore in Q3FY24 with an EBITDA margin of 29.60%. This marks an improvement of 591 bps YoY. The Profit After Tax (PAT) increased by 57% for Q3FY25 to Rs 46.78 crore, compared to Rs 29.78 crore in Q3FY24. The PAT Margin stood at 25.2% in Q3FY25, compared to 21.30% in Q3FY24. Satish Wagh, Chairman and Whole Time Director, Supriya Lifescience, commenting on the results, said, “Our Q3FY25 results underscore Supriya Lifescience’s commitment to delivering value through operational excellence and strategic growth initiatives. The 33% YoY revenue growth and a remarkable 45% surge in gross profit reflect our strong market presence and efficient execution across therapeutic segments. The steady improvement in our EBITDA and PAT margins, reaching 35% and 25% respectively, highlights our ability to maintain profitability while investing in sustainable growth." Result PDF
Conference Call with Supriya Lifescience Management and Analysts on Q3FY25 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Supriya Lifescience announced H1FY25 & Q2FY25 results In the second quarter of FY25, Supriya Lifescience Ltd. witnessed remarkable growth in its revenue, reporting a 18.6 % year-over-year increase, reaching Rs 166.1 crore compared to Rs 140.1 crore in Q2FY24. Gross Profit for Q2FY255 stood at Rs 120.13 crore, with a growth of 53.1% compared to Rs 78.46 crore in Q2FY24. EBITDA for Q2FY255 stood at Rs 64.72 crore, with an EBITDA Margin of 39.0%, as opposed to an EBITDA of Rs 31.75 crore in Q2FY24 with an EBITDA margin of 22.7%. This marks a growth of 103.8% YoY. The Profit After Tax (PAT) for Q2FY255 came at Rs 46.15 crore, compared to Rs 23.88 crore in Q2FY24. The PAT Margin stood at 27.8% in Q2FY255, compared to 17.0% in Q2FY24. Analgesic and Anaesthetic segment led the business growth in Q2 contributing 54.9% to the revenue vs 50.0% in Q2FY24. Anti-Asthmatic segment contributed 9.2% compared to 7.2%. European markets now contribute 45% of our business revenue in H1FY25 up from 39% in H1FY24. For Anaesthetic therapy 3 ANDA projects have been initiated and company is also working on ANDA projects for Anti Hypertensive and Vitamins. Capacity Utilisation has quickly increased from 47% in FY22 following a fresh capacity addition to 86% in FY24. In order to support future growth of various business segments the company has acquired three separate land parcels near different plants. Supriya Lifescience Ltd. continues to expand its global footprint, now doing business with over 1,700 customers across more than 128 countries. To ensure sustained growth and further expansion through new customer acquisition, the company has strategically distributed these geographic regions among its dedicated sales teams Satish Wagh, Executive Chairman & WTD, Supriya Lifescience commenting on the results, said: “Our commitment to innovation through R&D; is paving the way for sustained growth and expansion. With the commissioning of our advanced R&D; lab at Lote Parshuram and the upcoming Ambernath facility, we’re focusing on new product development and CMO/CDMO opportunities to complement our existing portfolio. Expanding our global presence across key regions, we're also working closely with regulatory and sales teams to acquire new customers, particularly in regulated markets. Our recent exclusive 10-year contract with a leading European firm underscores our capabilities in handling complex chemical processes, setting the stage for similar opportunities. As we enhance our infrastructure, including increasing capacity at Lote Parshuram to 1,020 KL by Q3FY25, we’re building a foundation for a stronger future." Result PDF